Ocular Therapeutix. has been granted a patent for an intracanalicular injectable applicator device designed to deliver injectables through the lacrimal punctum. The device features a cannula for storage, a tip structure for punctum dilation, and an actuating mechanism to facilitate the injection process. GlobalData’s report on Ocular Therapeutix gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ocular Therapeutix, Nanoparticle drug conjugates was a key innovation area identified from patents. Ocular Therapeutix's grant share as of July 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Intracanalicular injectable applicator device for drug delivery
The granted patent US12023276B2 describes an innovative intracanalicular injectable applicator device designed for administering injectable treatments through the lacrimal punctum. The device features a body that houses a cavity and a cannula, which is aligned with the cavity and designed to store an injectable solution. A tip structure is integrated into the device, which dilates the lacrimal punctum upon insertion into the canaliculus. This tip structure has a specific Shore A durometer range of 50 to 120 and an opening smaller than the injectable's outer diameter, ensuring precise delivery. The device also includes an actuating structure that facilitates the injection of the solution through the cannula and into the canaliculus.
Further claims detail the construction and functionality of the actuating structure, which includes a plunger and a push-wire mechanism. The plunger is designed to fit within the body cavity and is equipped with hooked clips to prevent separation from the body. Additionally, the plunger's non-circular profile aligns with a corresponding cavity profile to ensure proper actuation. The patent also outlines methods for using the device, including loading the injectable, inserting the tip structure, and actuating the device to deliver the injectable. The injectable substances mentioned include travoprost, cyclosporine, and dexamethasone, indicating potential applications in treating various ocular conditions.
To know more about GlobalData’s detailed insights on Ocular Therapeutix, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
